Literature DB >> 22588242

Coated transjugular intrahepatic portosystemic shunt does not improve thrombocytopenia in patients with liver cirrhosis.

Elise J Barney1, Ester C Little, Richard D Gerkin, Alberto X Ramos, Jeffrey Kahn, Mark Wong, Geetha Kolli, Richard Manch.   

Abstract

BACKGROUND/AIM: Thrombocytopenia is a common complication of chronic liver disease. The theory of portal decompression to improve thrombocytopenia due to hypersplenism has led to the study of transjugular intrahepatic portosystemic shunt (TIPS) as a potential therapy. However, there is a paucity of data and results have been conflicting. The aim of this study was to determine whether platelet counts improved in cirrhotic patients after placement of the new polytetrafluoroethylene (PTFE)-coated TIPS, developed in 2004.
METHODS: This is a retrospective cohort study of 68 patients with chronic liver disease who underwent a TIPS procedure. One-hundred twenty controls who did not undergo a TIPS procedure were matched on average for age, sex, race, model for end-stage liver disease (MELD) score, and etiology of liver disease. Platelet and hemoglobin counts were recorded during the month prior to the TIPS procedure (baseline) and over the following 12-14 months or until transplanted or death.
RESULTS: While platelet counts improved during the first 3 months after TIPS with a mean increase of 11.25 × 103/μL (p = 0.064), they returned to baseline (pre-TIPS) with mean platelets of 91.31 × 103 μL by 12-14 months in comparison with a mild decrease of 10.2 × 103 μL in platelet counts in the control group from 100.4 × 103 μL to 90.2 × 103 (p = 0.119). There was also no significant correlation between platelet counts and etiology of liver disease, age, race, gender, or MELD score. Hemoglobin counts were found to have a small increase of 0.657 g/dL over the 12-14 month course in the TIPS group, which was statistically significant (p = 0.003).
CONCLUSION: There does not appear to be a significant improvement in thrombocytopenia in cirrhotic patients after TIPS placement, despite advances in TIPS stents. However, there may be a mild improvement in anemia after TIPS implantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22588242     DOI: 10.1007/s10620-012-2162-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

Review 1.  Thrombopoietin.

Authors:  K Kaushansky
Journal:  N Engl J Med       Date:  1998-09-10       Impact factor: 91.245

2.  Prospective evaluation of haematological alterations following the transjugular intrahepatic portosystemic stent-shunt (TIPSS).

Authors:  R Jalan; D N Redhead; P L Allan; P C Hayes
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-04       Impact factor: 2.566

3.  Effect of portasystemic shunt on hypersplenism: clinical study in 129 patients with cirrhosis.

Authors:  M Puttini; A Marni; F Montes; L Belli
Journal:  Am Surg       Date:  1979-07       Impact factor: 0.688

Review 4.  Splenomegaly, hypersplenism and coagulation abnormalities in liver disease.

Authors:  P A McCormick; K M Murphy
Journal:  Baillieres Best Pract Res Clin Gastroenterol       Date:  2000-12

5.  Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis.

Authors:  Z Karasu; A Gurakar; B Kerwin; S Hulagu; A Jazzar; R McFadden; B Nour; A Sebastian; F Cassidy; K Stokes; D H Van Thiel; H Wright
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

Review 6.  Thrombocytopenia in liver disease.

Authors:  Edoardo G Giannini; Vincenzo Savarino
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

Review 7.  Thrombocytopenia associated with chronic liver disease.

Authors:  Nezam Afdhal; John McHutchison; Robert Brown; Ira Jacobson; Michael Manns; Fred Poordad; Babette Weksler; Rafael Esteban
Journal:  J Hepatol       Date:  2008-03-31       Impact factor: 25.083

8.  The hematologic consequences of transjugular intrahepatic portosystemic shunts.

Authors:  A J Sanyal; A M Freedman; P P Purdum; M L Shiffman; V A Luketic
Journal:  Hepatology       Date:  1996-01       Impact factor: 17.425

9.  Improvement of thrombocytopenia due to hypersplenism after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients.

Authors:  O A Alvarez; G A Lopera; V Patel; C E Encarnacion; J C Palmaz; M Lee
Journal:  Am J Gastroenterol       Date:  1996-01       Impact factor: 10.864

10.  Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS). A retrospective analysis.

Authors:  S P Lawrence; D C Lezotte; J D Durham; D A Kumpe; G T Everson; B M Bilir
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

View more
  3 in total

1.  Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.

Authors:  Theresa Bucsics; Katharina Lampichler; Constantin Vierziger; Maria Schoder; Florian Wolf; David Bauer; Benedikt Simbrunner; Lukas Hartl; Mathias Jachs; Bernhard Scheiner; Michael Trauner; Thomas Gruenberger; Franz Karnel; Mattias Mandorfer; Thomas Reiberger
Journal:  Dig Dis Sci       Date:  2022-03-17       Impact factor: 3.199

2.  Portocaval shunt for hepatocyte package: challenging application of small intestinal graft in animal models.

Authors:  Junji Iwasaki; Toshiyuki Hata; Shinji Uemoto; Yasuhiro Fujimoto; Hiroyuki Kanazawa; Takumi Teratani; Shuji Hishikawa; Eiji Kobayashi
Journal:  Organogenesis       Date:  2013-08-08       Impact factor: 2.500

3.  Efficacy and safety of laparoscopic splenectomy for hypersplenism secondary to portal hypertension after transjugular intrahepatic portosystemic shunt.

Authors:  Yingying Li; Zuojin Liu; Chang'an Liu
Journal:  BMC Gastroenterol       Date:  2021-02-11       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.